A comparison of the direct medical costs for individuals with or without basal or squamous cell skin cancer: A study from Australia
Objectives: The composition of the medical costs incurred by people treated for basal cell and squamous cell carcinomas (hereafter keratinocyte cancers) is not adequately understood. We sought to compare the medical costs of individuals with or without keratinocyte cancers. Methods: We used national...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2016-05-01
|
Series: | SAGE Open Medicine |
Online Access: | https://doi.org/10.1177/2050312116646030 |
id |
doaj-7e7579525b854fad8d813b98d6192891 |
---|---|
record_format |
Article |
spelling |
doaj-7e7579525b854fad8d813b98d61928912020-11-25T03:00:39ZengSAGE PublishingSAGE Open Medicine2050-31212016-05-01410.1177/205031211664603010.1177_2050312116646030A comparison of the direct medical costs for individuals with or without basal or squamous cell skin cancer: A study from AustraliaDavid Rowell0Louisa G Gordon1Catherine M Olsen2David C Whiteman3The University of Queensland, Queensland Brain Institute, Asia-Pacific Centre for Neuromodulation, St Andrews War Memorial Hospital, Brisbane, QLD, AustraliaCentre for Applied Health Economics, Menzies Health Institute Queensland, Griffith University, Brisbane, QLD, AustraliaQIMR Berghofer Medical Research Institute, Population Health Department, Royal Brisbane Hospital, Brisbane, QLD, AustraliaQIMR Berghofer Medical Research Institute, Population Health Department, Royal Brisbane Hospital, Brisbane, QLD, AustraliaObjectives: The composition of the medical costs incurred by people treated for basal cell and squamous cell carcinomas (hereafter keratinocyte cancers) is not adequately understood. We sought to compare the medical costs of individuals with or without keratinocyte cancers. Methods: We used national health insurance data to analyze the direct medical costs of 2000 cases and 2000 controls nested within the QSkin prospective cohort study (n = 43,794) conducted in Australia. We reconstructed the medical history of patients using medical and pharmaceutical item codes and then compared the health service costs of individuals treated for keratinocyte cancers with those not treated for keratinocyte cancers. Results: Individuals treated for keratinocyte cancers consumed on average AUD$1320 per annum more in medical services than those without keratinocyte cancers. Only 23.2% of costs were attributed to the explicit treatment of keratinocyte cancers. The principal drivers of the residual costs were medical attendances, surgical procedures on the skin, and histopathology services. We found significant positive associations between history of treatment for keratinocyte cancers with treatments for other health conditions, including melanoma, cardiovascular disease, lipidemia, osteoporosis, rheumatoid arthritis, colorectal cancer, prostate cancer, and tuberculosis. Conclusion: Individuals treated for keratinocyte cancers have substantially higher medical costs overall than individuals without keratinocyte cancers. The direct costs of skin cancer excision account for only one-fifth of this difference.https://doi.org/10.1177/2050312116646030 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
David Rowell Louisa G Gordon Catherine M Olsen David C Whiteman |
spellingShingle |
David Rowell Louisa G Gordon Catherine M Olsen David C Whiteman A comparison of the direct medical costs for individuals with or without basal or squamous cell skin cancer: A study from Australia SAGE Open Medicine |
author_facet |
David Rowell Louisa G Gordon Catherine M Olsen David C Whiteman |
author_sort |
David Rowell |
title |
A comparison of the direct medical costs for individuals with or without basal or squamous cell skin cancer: A study from Australia |
title_short |
A comparison of the direct medical costs for individuals with or without basal or squamous cell skin cancer: A study from Australia |
title_full |
A comparison of the direct medical costs for individuals with or without basal or squamous cell skin cancer: A study from Australia |
title_fullStr |
A comparison of the direct medical costs for individuals with or without basal or squamous cell skin cancer: A study from Australia |
title_full_unstemmed |
A comparison of the direct medical costs for individuals with or without basal or squamous cell skin cancer: A study from Australia |
title_sort |
comparison of the direct medical costs for individuals with or without basal or squamous cell skin cancer: a study from australia |
publisher |
SAGE Publishing |
series |
SAGE Open Medicine |
issn |
2050-3121 |
publishDate |
2016-05-01 |
description |
Objectives: The composition of the medical costs incurred by people treated for basal cell and squamous cell carcinomas (hereafter keratinocyte cancers) is not adequately understood. We sought to compare the medical costs of individuals with or without keratinocyte cancers. Methods: We used national health insurance data to analyze the direct medical costs of 2000 cases and 2000 controls nested within the QSkin prospective cohort study (n = 43,794) conducted in Australia. We reconstructed the medical history of patients using medical and pharmaceutical item codes and then compared the health service costs of individuals treated for keratinocyte cancers with those not treated for keratinocyte cancers. Results: Individuals treated for keratinocyte cancers consumed on average AUD$1320 per annum more in medical services than those without keratinocyte cancers. Only 23.2% of costs were attributed to the explicit treatment of keratinocyte cancers. The principal drivers of the residual costs were medical attendances, surgical procedures on the skin, and histopathology services. We found significant positive associations between history of treatment for keratinocyte cancers with treatments for other health conditions, including melanoma, cardiovascular disease, lipidemia, osteoporosis, rheumatoid arthritis, colorectal cancer, prostate cancer, and tuberculosis. Conclusion: Individuals treated for keratinocyte cancers have substantially higher medical costs overall than individuals without keratinocyte cancers. The direct costs of skin cancer excision account for only one-fifth of this difference. |
url |
https://doi.org/10.1177/2050312116646030 |
work_keys_str_mv |
AT davidrowell acomparisonofthedirectmedicalcostsforindividualswithorwithoutbasalorsquamouscellskincancerastudyfromaustralia AT louisaggordon acomparisonofthedirectmedicalcostsforindividualswithorwithoutbasalorsquamouscellskincancerastudyfromaustralia AT catherinemolsen acomparisonofthedirectmedicalcostsforindividualswithorwithoutbasalorsquamouscellskincancerastudyfromaustralia AT davidcwhiteman acomparisonofthedirectmedicalcostsforindividualswithorwithoutbasalorsquamouscellskincancerastudyfromaustralia AT davidrowell comparisonofthedirectmedicalcostsforindividualswithorwithoutbasalorsquamouscellskincancerastudyfromaustralia AT louisaggordon comparisonofthedirectmedicalcostsforindividualswithorwithoutbasalorsquamouscellskincancerastudyfromaustralia AT catherinemolsen comparisonofthedirectmedicalcostsforindividualswithorwithoutbasalorsquamouscellskincancerastudyfromaustralia AT davidcwhiteman comparisonofthedirectmedicalcostsforindividualswithorwithoutbasalorsquamouscellskincancerastudyfromaustralia |
_version_ |
1724696900626546688 |